limit
pitfal
past
decad
molecular
method
detect
quantif
viru
infect
replac
mani
tradit
viral
cultur
serolog
method
molecular
test
significantli
improv
clinic
turnaround
time
reduc
handson
time
addit
increas
diagnost
sensit
specif
mani
commerci
assay
kit
automat
instrument
avail
allow
mani
clinic
microbiolog
laboratori
offer
molecular
test
howev
routin
implement
nucleic
acid
dna
rna
amplif
hybrid
methodolog
clinic
laboratori
still
associ
number
limit
increas
costtest
due
expens
instrument
reagent
amplif
carryov
contamin
standard
posit
neg
quantit
control
integr
coamplifi
intern
dna
control
demonstr
absenc
polymeras
chain
reaction
pcr
inhibitor
amplif
prevent
falseposit
falseneg
report
due
antigen
pathogen
nucleic
acid
sequenc
drift
accur
interpret
data
softwar
analys
specimen
collect
adequ
specimen
import
molecular
diagnosi
viru
specimen
type
commonli
use
molecular
diagnosi
whole
blood
ml
collect
edta
lavend
top
tube
store
c
freez
plasma
collect
ml
whole
blood
edta
acd
solut
ppt
steril
tube
store
whole
blood
room
temperatur
c
h
remov
plasma
cell
within
h
collect
centrifug
g
min
clarifi
filtrat
centrifug
store
plasma
c
within
min
separ
plasma
may
also
store
c
nonfrostfre
freezer
h
colder
freezer
avail
ship
dri
ice
overnight
deliveri
minimum
volum
specimen
ml
plasma
urin
first
ml
void
urin
collect
steril
urinalysi
contain
ml
steril
screw
cap
tube
prefer
store
c
less
h
store
c
long
term
bronchial
lavagetrach
aspir
ml
collect
steril
tube
store
c
less
h
bone
marrow
ml
collect
edta
tube
store
c
freez
tissu
tissu
block
collect
steril
screwtop
contain
add
small
amount
salin
keep
moist
avoid
use
viral
transport
media
avoid
potenti
inhibit
pcr
fresh
tissu
store
c
immedi
preserv
nucleic
acid
paraffinembed
tissu
accept
usual
section
mm
thick
suffici
pcr
analysi
tissu
section
must
deparaffin
xylen
dna
extract
fecal
steril
swab
plastic
shaft
small
fecal
sampl
place
ml
steril
salin
contain
tight
fit
lid
use
viral
transport
media
avoid
potenti
inhibit
pcr
swab
steril
swab
plastic
shaft
place
ml
steril
salin
use
viral
transport
media
avoid
potenti
inhibit
pcr
cerebrospin
fluid
csf
ml
fluid
submit
steril
leakproof
tube
store
c
less
h
store
c
long
term
assay
perform
analysi
analyt
perform
analyt
sensit
determin
lowest
number
target
detect
assay
crossreact
specif
determin
assay
produc
falseposit
result
presenc
high
concentr
similar
unrel
pathogen
bacteria
yeast
viru
linear
evalu
log
differ
expect
concentr
differ
within
log
ratio
observ
mean
quantit
expect
concentr
within
quantit
rang
measur
concentr
within
linear
rang
good
reproduc
clinic
perform
limit
detect
lowest
concentr
target
nucleic
acid
detect
detect
cutoff
replic
usual
replic
detect
cutoff
point
assay
quantit
scale
neg
specimen
produc
result
cutoff
confid
limit
quantif
lowest
concentr
target
nucleic
acid
quantifi
replic
reproduc
reproduc
test
usual
establish
test
three
six
sampl
panel
known
concentr
target
triplic
quadrupl
commerci
panel
use
establish
paramet
avail
reproduc
express
percent
correl
coeffici
quantit
assay
cv
rang
precis
reproduc
test
result
eg
interand
intratechnologist
interand
intraassay
sensit
true
posit
sampl
true
posit
sampl
limit
detect
specif
true
neg
sampl
true
neg
sampl
limit
detect
qualiti
control
quantit
assay
addit
qualiti
control
procedur
perform
includ
calibr
calibr
verif
calibr
set
oper
establish
specifi
condit
relationship
reagent
system
instrument
respons
correspond
concentrationact
valu
analyt
calibr
procedur
typic
specifi
method
manufactur
may
also
establish
laboratori
calibr
verif
denot
process
confirm
current
calibr
set
remain
valid
method
recalibr
calibr
verif
analyt
measur
rang
valid
must
perform
least
everi
month
run
sensit
control
includ
addit
posit
neg
control
recommend
two
level
control
high
low
includ
human
immunodefici
viru
hiv
rna
retroviru
belong
lentiviru
famili
genet
differ
share
nucleotid
homolog
relat
siv
type
appear
caus
clinic
indistinguish
aid
howev
seem
less
easili
transmit
period
initi
infect
ill
longer
case
worldwid
predomin
viru
gener
peopl
refer
hiv
without
specifi
type
viru
refer
rel
uncommon
concentr
west
africa
rare
found
elsewher
structur
hiv
virion
fig
hiv
viru
consist
spheric
viral
particl
encas
lipid
bilay
deriv
host
cell
cover
protrud
peglik
structur
compos
glycoprotein
viru
core
nucleocapsid
contain
major
capsid
protein
two
copi
genom
rna
three
viral
enzym
proteas
revers
transcriptas
integras
viral
replic
fig
first
step
infect
entri
host
cell
requir
bind
molecul
viru
molecul
host
cell
surfac
mediat
molecul
two
surfac
molecul
chemokin
receptor
betachemokin
alphachemokin
also
requir
entri
bound
viral
envelop
fuse
cell
membran
viru
rna
enzym
enter
cytoplasm
revers
transcriptas
catalyz
first
synthesi
dna
copi
viral
rna
second
synthesi
second
dna
strand
complementari
first
one
therefor
doublestrand
dna
dsdna
gener
integras
facilit
integr
viral
dna
cellular
chromosom
cell
divid
provid
latenc
enabl
viru
effect
evad
host
respons
transcript
dna
result
product
rna
rna
serv
genom
new
virus
translat
produc
viral
protein
viral
protein
facilit
proteas
assembl
viral
particl
use
host
cell
proteinmak
machineri
complet
hiv
particl
assembl
macrophag
hiv
bud
cell
without
ruptur
cell
cycl
begin
cell
hiv
exit
cell
ruptur
effect
kill
cell
gag
pol
env
gene
encod
structur
protein
new
viru
particl
six
gene
tat
rev
nef
vif
vpr
vpu
regul
synthesi
assembl
viral
particl
phylogen
analysi
nucleotid
sequenc
env
gene
enabl
classif
three
group
major
n
nonm
outlier
group
infect
classifi
nine
differ
genet
subtyp
ak
infect
belong
group
subtypeclass
b
preval
develop
world
hiv
transmit
via
sexual
contact
blood
via
transfus
blood
product
contamin
needl
passag
mother
child
utero
birth
ingest
breast
milk
although
saliva
contain
small
quantiti
viru
viru
spread
kiss
hiv
spread
fecalor
rout
aerosol
insect
casual
contact
hiv
caus
agent
acquir
immunodefici
syndrom
aid
lead
caus
death
human
age
year
two
main
target
hiv
immun
system
central
nervou
system
hiv
target
cell
monocytesmacrophag
langerhan
cellsdendrit
cell
caus
sever
immunosuppress
neuropatholog
symptom
dementia
mening
encephalopathi
host
common
opportunist
infect
pneumocysti
carinii
candidiasi
tuberculosi
cryptococcu
cytomegaloretin
common
malign
kaposi
sarcoma
lymphoma
nonhodgkin
brain
primari
uterin
carcinoma
individu
hiv
face
long
challeng
road
diseas
steadi
natur
histori
start
asymptomat
state
progress
toward
aid
natur
histori
includ
three
phase
earlystag
hiv
infect
defin
presenc
hiv
count
greater
earli
stage
develop
week
initi
exposur
selflimit
flulik
symptom
resolv
week
later
patient
high
level
viral
product
viremia
widespread
seed
lymphoid
tissu
chronic
phase
hiv
infect
occur
count
chronic
phase
associ
period
latenc
immun
system
intact
continu
hiv
replic
may
last
year
patient
either
asymptomat
develop
persist
lymphadenopathi
minor
opportunist
infect
candidiasi
herp
zoster
count
drop
hiv
infect
enter
crisi
phase
certain
infect
easili
handl
intact
immun
system
take
advantag
immunocompromis
state
opportunist
infect
certain
cancer
may
also
appear
reason
patient
count
less
least
one
opportunist
infect
cancer
specif
seen
crisi
phase
hiv
offici
design
aid
specimen
whole
blood
serum
plasma
tabl
convent
test
problem
lymphocyt
count
cell
also
call
cell
thelper
cell
primari
target
hiv
viru
quantit
cell
first
effect
predictor
hiv
progress
count
one
mani
factor
includ
clinic
statu
hiv
viral
load
medic
adher
assess
start
chang
antiretrovir
arv
treatment
cell
count
cellsmm
import
determin
stage
hiv
diseas
indic
need
prophylaxi
opportunist
pathogen
laboratori
report
count
part
list
sever
type
lymphocyt
absolut
count
rel
percentag
measur
trend
percentag
addit
absolut
count
must
perform
prior
initi
adjust
arv
treatment
manag
decis
percentag
sometim
use
coordin
absolut
valu
assess
signific
chang
absolut
count
absolut
count
fluctuat
overal
lymphocyt
count
vari
percentag
often
remain
stabl
insignific
fluctuat
cell
cytotox
cell
count
appear
predict
clinic
outcom
monitor
purpos
count
repeat
approxim
everi
month
stabl
untreat
patient
patient
stabl
art
count
check
frequent
accord
clinic
situat
viral
cultur
although
specif
singl
posit
cultur
must
confirm
second
specimen
rare
use
due
high
cost
laborintens
less
sensit
antibodi
test
neg
cultur
may
caus
technic
problem
defect
viru
inabl
viru
replic
cultur
serolog
studi
antigen
earli
develop
assay
detect
hiv
infect
screen
donat
blood
hiv
advantag
detect
hiv
infect
prior
develop
antibodi
disadvantag
limit
util
due
short
window
time
use
test
unavail
whole
blood
store
c
longer
h
plasma
must
separ
within
h
collect
centrifug
g
min
room
temperatur
transfer
polypropylen
tube
prevent
viral
degrad
plasma
may
store
c
day
frozen
c
specimen
store
ul
aliquot
steril
ml
polypropylen
tube
freezethaw
studi
shown
specimen
may
test
three
freezethaw
cycl
without
loss
viral
rna
hiv
genotyp
plasma
specimen
anticoagul
edta
specimen
must
anticoagul
heparin
whole
blood
store
c
longer
h
plasma
separ
within
min
later
min
centrifug
g
min
c
transfer
polypropylen
tube
plasma
may
store
frozen
c
month
sampl
may
test
two
freezethaw
cycl
plasma
specimen
contain
follow
shown
interfer
result
lipid
mgml
bilirubin
mgml
hemoglobin
mgml
antibodi
screen
assay
qualit
detect
antibodi
hiv
common
way
diagnos
hiv
infect
adult
children
month
old
antibodi
usual
detect
within
week
infect
individu
seroconvert
week
although
may
detect
month
year
window
period
time
infect
develop
antibodi
person
infect
hiv
take
week
bodi
make
antibodi
viru
peopl
develop
antibodi
within
month
infect
although
peopl
take
month
rare
case
take
month
test
posit
gener
repeat
test
hiv
occur
month
signific
concern
recent
hiv
infect
addit
level
viru
blood
high
window
period
peopl
easili
transmit
hiv
serolog
hiv
antibodi
screen
test
highli
sensit
elisa
rapid
test
home
test
requir
followup
preliminari
posit
specimen
highli
specif
hiv
antibodi
confirmatori
assay
western
blot
fig
elisa
method
common
earliest
develop
antibodi
screen
assay
home
access
test
system
analyz
driedblood
spot
finger
stick
collect
filter
paper
home
sent
test
facil
rapid
test
hiv
assay
detect
antibodi
hiv
within
minut
rapid
test
highli
specif
neg
mean
neg
except
window
period
test
also
highli
sensit
posit
mean
like
hiv
must
confirm
use
western
blot
hiv
diagnosi
confirmatori
antibodi
assay
western
blot
gold
standard
hiv
diagnost
test
viru
disrupt
individu
protein
separ
molecular
weight
via
differenti
migrat
polyacrylamid
gel
blot
onto
membran
support
hiv
serum
antibodi
patient
allow
bind
protein
membran
support
pattern
reactiv
visibl
read
detect
three
major
proteinsvir
band
core
protein
two
envelop
protein
reactiv
wb
demonstr
antibodi
two
three
major
band
nonreact
wb
detect
viral
band
fig
repeat
reactiv
elisa
reactiv
confirmatori
assay
report
posit
antibodi
nonreact
specimen
elisa
repeatedli
reactiv
elisa
nonreact
confirmatori
assay
neg
antibodi
wb
serum
antibodi
bind
combin
viral
band
consid
indetermin
followup
blood
specimen
obtain
month
later
repeat
hiv
antibodi
test
individu
repeat
indetermin
result
undergo
test
use
molecular
assay
pcr
least
sensit
specif
screen
assay
although
sensit
detect
earli
seroconvers
disadvantag
laborintens
prone
subject
interpret
costli
screen
assay
altern
antibodi
screen
assay
qualit
us
food
drug
administr
fda
approv
assay
test
bodi
fluid
blood
detect
antibodi
although
sensit
specif
less
reliabl
util
test
algorithm
serum
elisa
follow
wb
serum
sampl
produc
reaction
elisa
consid
neg
report
absenc
hiv
antibodi
patient
hiv
infect
retest
month
recent
risk
event
transcriptas
region
genom
use
rtpcr
amplifi
dna
sequenc
yield
nucleotid
profil
viru
use
sequenc
gel
sequenc
gener
compar
wildtyp
sequenc
differ
confer
drug
resist
highlight
anoth
fdaapprov
assay
dna
sequenc
genotyp
system
celera
diagnost
alameda
ca
distribut
abbott
laboratori
abbott
park
il
twostep
procedur
first
amplifi
proteas
revers
transcriptas
region
genom
use
rtpcr
cycl
sequenc
amplifi
dna
sequenc
yield
nucleotid
profil
viru
use
capillari
electrophoresi
minimum
input
viral
rna
assay
copiesml
use
ml
plasma
success
genotyp
pitfal
genotyp
genotyp
variant
compris
less
sampl
may
detect
genotyp
result
reflect
predomin
subtyp
interpret
genotyp
result
base
clade
b
preval
clade
develop
world
howev
subtyp
recombin
may
undetect
assess
resist
complic
replic
kinet
resist
mutant
resist
mutant
often
less
fit
wildtyp
viru
may
becom
undetect
select
drug
nevertheless
mutant
persist
patient
select
drug
pressur
reappli
mutant
replic
resist
popul
quickli
predomin
plasma
hiv
rna
surrog
marker
hiv
diseas
progress
use
guid
monitor
therapi
manag
arv
therapi
implement
patient
follow
clinic
find
symptomat
hiv
infect
aidsdefin
condit
count
viral
load
copiesml
pregnant
mother
copiesml
initi
highli
activ
antiretrovir
therapi
haart
goal
arv
patient
attain
viral
load
copiesml
includ
ration
sequenc
arv
agent
achiev
maximum
possibl
viral
replic
suppress
arv
patient
patient
success
treatment
regimen
monitor
viral
load
measur
baselin
everi
week
initi
everi
month
maxim
suppress
attain
although
patient
count
cellsmm
may
requir
less
frequent
viral
load
monitor
typic
patient
begin
therapi
chang
therapi
result
virolog
failur
viral
load
measur
week
therapi
initi
decreas
least
log
indic
effect
therapi
patient
reach
goal
copiesml
within
month
absent
incomplet
respons
viral
load
arv
therapi
rais
concern
poor
patient
adher
therapi
andor
viral
resist
signific
increas
increas
viral
load
without
clear
explan
viral
load
repeat
confirm
virolog
failur
genotyp
resist
test
perform
prior
initi
treatment
arv
patient
patient
copiesml
nonrespons
arv
genotyp
resist
test
recommend
patient
copiesml
less
discontinu
arv
therapi
year
hepat
c
viru
hcv
first
recogn
nona
nonb
hepat
viru
nanbh
first
identifi
use
molecular
method
hcv
major
caus
nona
nonb
hepat
affect
world
popul
common
rout
transmiss
via
blood
blood
product
ie
immun
globulin
surgeri
intraven
drug
abus
significantli
reduc
advent
routin
blood
screen
sexual
transmiss
well
vertic
mother
infant
occur
rate
vertic
transmiss
hcv
hcv
posit
sens
singlestrand
rna
viru
repres
third
genu
famili
flavivirida
genom
encod
singl
open
read
frame
code
structur
one
core
two
envelop
protein
well
seri
nonstructur
protein
fig
untransl
region
constant
use
hcv
rna
assay
genotyp
core
region
constant
use
genotyp
assay
core
protein
assay
pcrrflp
riba
test
envelop
region
hypervari
region
associ
high
rate
mutat
quasispeci
region
code
proteas
region
code
proteasehelicas
riba
test
found
region
region
antigen
use
antihcv
riba
test
target
region
region
code
interferon
respons
element
region
code
rna
polymeras
antigen
use
antihcv
riba
test
target
area
hcv
consist
heterogen
group
genotyp
base
sequenc
homolog
untransl
region
current
type
subtyp
type
distribut
worldwid
type
respons
approxim
infect
type
occur
primarili
middl
east
type
south
africa
type
hong
kong
unit
state
us
approxim
peopl
infect
hcv
genotyp
other
type
genotyp
common
us
littl
differ
mode
transmiss
natur
histori
infect
among
differ
genotyp
cure
rate
antivir
therapi
notabl
higher
genotyp
durat
hcv
therapi
shorter
genotyp
infect
hcv
curabl
therapi
current
standard
treatment
base
rapid
separ
serum
plasma
cell
recommend
centrifug
within
h
collect
unsepar
edta
plasma
stabl
room
temperatur
h
collect
separ
serum
plasma
stabl
room
temperatur
day
refriger
temperatur
week
frozen
c
year
convent
test
problem
serolog
studi
enzym
immunoassay
eia
detect
hcv
antibodi
recommend
initi
test
identif
hcv
use
screen
risk
popul
eia
compar
inexpens
reproduc
carri
high
sensit
specif
eia
detect
antibodi
averag
week
infect
howev
window
period
patient
detect
viral
rna
undetect
level
antibodi
neg
enzym
immunoassay
usual
suffici
exclud
diagnosi
hcv
infect
immunocompet
patient
howev
test
fals
neg
immunodefici
endstag
renal
diseas
convers
falseposit
eia
may
occur
patient
autoimmun
disord
patient
assay
hcv
rna
necessari
diagnosi
chronic
infect
patient
seroconvert
usual
remain
posit
hcv
antibodi
thu
presenc
hcv
antibodi
may
reflect
remot
recent
infect
immunoblot
assay
still
use
supplement
assay
person
screen
nonclin
set
person
posit
eia
test
neg
hcv
rna
hcv
antibodi
assay
includ
antihcv
igm
assay
avid
test
signific
presenc
antihcv
igm
hcv
infect
unclear
antihcv
igm
report
patient
acut
hcv
patient
chronic
hcv
therefor
antihcv
igm
use
reliabl
marker
acut
hcv
infect
far
igm
assay
use
clinic
practic
howev
increas
serial
measur
antihcv
igm
titer
earli
onset
symptom
may
help
identifi
patient
acut
hcv
altern
increas
antihcv
igg
avid
index
within
week
onset
clinic
symptom
also
report
indic
acut
hcv
infect
paramet
could
use
togeth
antihcv
seroconvers
occur
baselin
sampl
avail
confirm
diagnosi
acut
infect
total
hcv
core
antigen
enzymelink
immunosorb
assay
elisa
hcv
ortho
assay
ortho
diagnost
detect
quantif
total
core
antigen
blood
hcv
core
protein
highli
antigen
induc
specif
cellular
humor
respons
probabl
play
pivot
role
pathogenesi
hcv
infect
avail
anticor
monoclon
antibodi
allow
develop
elisa
detect
hcv
core
ag
peripher
blood
patient
hcv
test
posit
antihcv
antibodi
prospect
lowrisk
popul
screen
total
hcv
core
antigen
elisa
quantit
ortho
clinic
diagnost
sensit
close
pcr
assay
diagnos
acut
hcv
infect
window
period
hcv
antibodi
develop
also
use
monitor
respons
antivir
treatment
elisa
hcv
use
three
recombin
antigen
origin
four
region
viral
genom
core
ortho
assay
quantit
immunoassay
total
free
antibodi
bound
hcv
nucleocapsid
core
antigen
assay
use
captur
elisa
format
differ
two
assay
elisa
hcv
ortho
assay
step
assay
disrupt
immun
complex
present
sampl
assay
intend
use
test
hcv
core
antigen
either
preseroconvers
acut
postseroconvers
chronic
phase
hcv
infect
less
expens
less
prone
carryov
pcr
test
use
rough
screen
correl
hcv
rna
load
howev
less
sensit
pcrbase
assay
individu
variat
higher
similar
technolog
use
architect
hcv
assay
abbot
laboratori
analyt
sensit
recent
develop
architect
hcv
assay
abbott
laboratori
abbott
park
il
vari
accord
hcv
genotyp
intern
unit
hcv
rna
per
millilit
iuml
drawback
total
hcv
core
ag
elisa
lower
limit
detect
hcvposit
patient
dialysi
often
low
hcv
rna
level
recombin
immunoblot
assay
riba
riba
develop
simultan
detect
antihcv
antibodi
hcv
core
antigen
riba
use
confirm
eia
result
sinc
earli
gener
high
rate
fals
posit
use
centrifug
ultracolumn
qiagen
process
larg
volum
ml
lod
improv
quantit
tabl
averag
unitsml
less
sensit
qualit
test
use
establish
baselin
viral
load
prior
therapi
monitor
chang
viral
load
therapi
pcr
two
realtim
pcr
platform
current
avail
detect
quantif
hcv
rna
coba
taqman
platform
use
togeth
autom
sampl
prepar
coba
ampliprep
system
capctm
roch
molecular
system
pleasanton
ca
abbott
platform
abbott
diagnost
chicago
il
use
amplif
platform
togeth
devic
sampl
prepar
art
lower
limit
detect
iuml
art
iuml
capctm
versant
hcv
rna
quantiplex
assay
bdna
bayer
signal
amplif
direct
nc
region
core
region
hcv
genom
microwel
plate
format
equival
detect
genotyp
lod
hcv
rna
copiesml
hcv
rna
copiesiu
broad
dynam
rang
iuml
compar
evalu
bayer
bdna
roch
pcr
viral
load
assay
demonstr
pcr
typespecif
oligonucleotid
probe
attach
nitrocellulos
strip
detect
sequenc
variat
found
nc
region
hcv
biotinlabel
pcr
product
hybrid
probe
strip
stringent
condit
hybrid
wash
streptavidinlabel
alkalin
phosphatas
ad
follow
incub
chromogen
result
develop
purplebrown
precipit
match
probe
biotinyl
pcr
product
hybrid
amplicon
one
line
strip
allow
classif
six
major
genotyp
common
subtyp
third
wave
technolog
invad
assay
third
wave
technolog
madison
wisconsin
new
dnascan
method
applic
term
cleavas
fragment
length
polymorph
cflp
reli
format
uniqu
secondari
structur
result
dna
allow
cool
follow
brief
heat
denatur
serv
substrat
structurespecif
cleavas
enzym
gener
set
cleavag
product
format
secondari
structur
sensit
nucleotid
sequenc
presenc
sequenc
polymorph
result
gener
uniqu
collect
cleavag
product
structur
fingerprint
target
wellconserv
ncr
hcv
determin
hcv
genotyp
need
initi
therapi
pegyl
ifna
ribavirin
determin
dose
ribavirin
treatment
durat
requir
hcv
resist
test
sever
amino
acid
substitut
confer
resist
directli
act
antivir
molecul
proteas
inhibitor
identifi
case
failur
tripl
combin
pegyl
ifna
ribavirin
either
telaprevir
boceprevir
hcv
variant
resist
compound
select
direct
sequenc
analysi
revers
hybrid
method
use
identifi
amino
acid
substitut
confer
resist
antivir
drug
ultradeep
sequenc
method
pyrosequenc
detect
minor
resist
popul
hcv
genosur
repres
first
seri
hcv
drug
resist
assay
develop
monogram
bioscienc
support
clinic
evalu
hcv
directact
antivir
daa
agent
use
manag
hcv
infect
hcv
genosur
analyz
genet
sequenc
nonstructur
protein
hcv
genotyp
encod
enzym
essenti
viral
replic
assay
detect
mutat
specif
identifi
associ
boceprevir
telaprevir
resist
pitfal
import
note
genotyp
bia
possibl
hcv
molecular
assay
extens
genet
heterogen
viru
falseposit
result
due
contamin
detect
neg
control
falseneg
result
due
amplif
inhibit
detect
intern
control
due
loss
bacteria
specimen
prepar
home
brew
pcr
assay
standard
variat
sampl
handl
laboratori
method
affect
sensit
assay
hcv
test
use
highrisk
patient
intraven
drug
user
children
born
hcvposit
mother
hivposit
patient
figur
show
algorithm
hcv
test
patient
suspect
chronic
hcv
infect
test
hcv
antibodi
patient
suspect
acut
infect
test
hcv
antibodi
also
hcv
rna
realtim
pcr
analysi
hcv
rna
repeat
patient
undergo
treatment
better
adjust
use
therapeut
agent
hcv
rna
test
perform
patient
posit
antihcv
test
patient
antivir
treatment
consid
use
quantit
assay
patient
unexplain
liver
diseas
whose
antihcv
test
neg
immun
compromis
suspect
acut
hcv
infect
hcv
genotyp
determin
hcvinfect
individu
prior
treatment
order
determin
durat
therapi
likelihood
respons
genotyp
analysi
shown
amino
acid
substitut
correl
resist
therapi
infect
cell
type
may
affect
lesser
extent
life
cycl
hbv
begin
attach
cell
surfac
cytoplasm
dna
still
core
capsid
remov
dna
pass
nucleu
form
coval
close
circular
dna
cccdna
hbv
use
host
transcript
machineri
replic
gene
use
rna
polymeras
ii
host
strand
cccdna
act
templat
transcript
transcript
mrna
translat
host
protein
synthesi
machineri
form
viral
protein
endoplasm
reticulum
protein
assembl
virion
secret
hbv
recogn
endem
china
part
asia
onethird
world
popul
activ
infect
hbv
hbv
strain
classifi
least
hbv
genotyp
j
sever
subtyp
base
nucleotid
homolog
surfac
gene
except
newli
identifi
genotyp
j
geograph
ethnic
distribut
hbv
genotyp
subtyp
well
character
genotyp
mainli
found
northwestern
europ
subtyp
north
america
africa
subtyp
wherea
genotyp
b
c
describ
southeastern
asian
popul
present
genotyp
b
divid
subtyp
among
isol
japan
found
east
asia
found
indigen
popul
live
arctic
alaska
northern
canada
greenland
genotyp
c
includ
subtyp
mainli
exist
east
southeast
asia
genotyp
e
f
seen
east
africa
new
world
respect
genotyp
often
found
southern
europ
part
central
asia
india
africa
middl
east
genotyp
g
recent
determin
genotyp
franc
america
germani
genotyp
h
report
patient
central
america
recent
genotyp
novel
intergenotyp
recombin
among
genotyp
c
g
isol
vietnam
lao
newest
hbv
genotyp
j
identifi
ryukyu
island
japan
genotyp
close
relationship
gibbonorangutan
genotyp
human
genotyp
c
acut
infect
genotyp
result
higher
rate
chronic
genotyp
b
c
compar
genotyp
b
case
patient
genotyp
c
lower
rate
spontan
hbv
e
antigen
hbeag
seroconvers
occur
tend
delay
hepat
genotyp
c
lower
respons
rate
genotyp
b
genotyp
c
also
associ
sever
liver
diseas
includ
hepatocellular
carcinoma
rate
new
hbv
infect
declin
approxim
sinc
nation
strategi
elimin
hbv
infect
implement
us
declin
greatest
among
children
born
sinc
routin
vaccin
children
first
recommend
transmit
parenter
sexual
contamin
open
cut
mucou
membran
long
incub
period
day
fig
asian
patient
like
vertic
infect
mother
child
african
western
patient
major
affect
patient
recov
ill
character
anorexia
nausea
vomit
headach
fever
abdomin
pain
dark
urin
sometim
jaundic
elev
transaminas
hyperbilirubinemia
elev
alkalin
phosphatas
may
also
occur
extrahepat
manifest
includ
arthralgia
arthriti
nephriti
dermat
patient
continu
carri
viru
marker
activ
viral
infect
greater
month
initi
infect
small
percentag
may
develop
chronic
persist
hepat
sequenc
fibrosi
cirrhosi
incid
hcc
increas
viral
genom
found
integr
cellular
dna
case
may
associ
polyarter
cryoglobulinemia
recent
sever
clinic
score
system
nomogram
consist
previous
confirm
independ
risk
predictor
sex
age
famili
histori
hcc
alcohol
consumpt
serum
alanin
aminotransferas
alt
level
hbeag
statu
serum
hbv
dna
level
andor
hbv
genotyp
introduc
easytous
nomogram
base
noninvas
clinic
characterist
found
accur
predict
hcc
risk
either
communityor
hospitalbas
hbvinfect
person
detect
hbv
dna
human
plasma
intend
use
screen
donor
hbv
dna
detect
limit
copiesml
target
gene
quantit
use
establish
baselin
viral
load
prior
therapi
monitor
chang
viral
load
therapi
digen
hbv
dna
hybrid
captur
ii
detect
quantit
hbv
dna
serum
limit
detect
hbv
dna
copiesml
quantit
rang
hbv
copiesml
pcr
amplicor
hbv
monitor
semiautom
coba
hbv
amplicor
monitor
test
roch
detect
quantit
hbv
dna
serum
plasma
use
primer
amplifi
sequenc
within
highli
conserv
precorecor
region
hbv
genom
amplifi
genotyp
e
equal
reduc
amplif
genotyp
f
g
limit
detect
copiesml
quantit
rang
copiesml
realtim
pcr
lightcyclerfret
hybrid
probe
target
fragment
gene
quantit
rang
copiesml
realtim
pcr
roch
taqman
assay
util
fret
technolog
probe
base
detect
amplicon
temperatur
cycl
target
gene
limit
detect
copiesml
quantit
rang
hbv
iuml
copiesml
iu
copi
bdna
assay
versant
hepat
b
viru
dna
assay
bayer
corpor
signal
amplif
direct
nc
region
core
region
hcv
genom
microwel
plate
format
limit
detect
copiesml
quantit
rang
hbv
dna
copiesml
equival
detect
genotyp
f
genotyp
mutat
analysiscurr
use
mainli
epidemiolog
purpos
rare
need
clinic
purpos
line
probe
assaylipa
innolipa
hbv
genotyp
assay
innogenet
nv
ghent
belgium
method
base
revers
hybrid
principl
biotinyl
amplicon
hybrid
specif
oligonucleotid
probe
immobil
parallel
line
membranebas
strip
amplifi
region
analyz
overlap
sequenc
encod
major
hydrophil
region
hbsag
sequenc
phylogenet
analysi
region
hbv
genom
identifi
hbv
genotyp
drug
resist
mutat
antihb
escap
mutat
base
comparison
dna
sequenc
pitfal
analyt
sensit
specif
current
realtim
pcr
assay
allow
accur
quantif
rang
approxim
log
suffici
quantifi
high
hbv
dna
level
found
certain
hbvinfect
patient
necessit
retest
sampl
dilut
factor
quantif
error
equal
quantif
hbv
genotyp
robust
quantif
case
nucleotid
polymorph
valid
current
commerci
realtim
pcr
assay
current
uniform
tendenc
report
hbv
dna
level
standard
unit
copiesml
genom
equivalentsml
iuml
assay
current
regist
use
plasma
serum
precis
threshold
hbv
dna
establish
could
guid
medic
decis
viral
load
test
use
assess
monitor
respons
therapi
hbv
infect
fig
hbv
carrier
activ
liver
diseas
hbv
dna
load
measur
assess
patient
regard
need
either
interferon
alpha
lamivudin
dna
polymeras
inhibitor
antivir
therapi
also
monitor
effect
increas
hbv
viral
load
also
use
marker
emerg
lamivudineresist
viral
mutant
activ
chronic
infect
hbv
treat
lamivudin
requir
surveil
emerg
lamivudineresist
viral
mutant
lamivudin
monotherapi
point
mutat
activ
site
polymeras
gene
ymdd
variant
occur
frequenc
year
phase
iii
studi
asian
patient
year
therapi
respect
emerg
lamivudin
resist
detect
rise
hbv
viral
load
confirm
sequenc
activ
site
dna
polymeras
gene
concord
cmv
antigen
test
result
also
ad
benefit
increas
specimen
stabil
smaller
requir
specimen
volum
abil
perform
patient
depress
white
blood
cell
count
result
pitfal
falseposit
result
due
contamin
detect
neg
control
falseneg
result
due
amplif
inhibit
detect
intern
control
due
loss
bacteria
specimen
prepar
lack
standard
process
differ
techniqu
assay
differ
quantit
method
differ
tissu
blood
compart
test
thu
make
interpret
result
across
studi
challeng
quantit
pcr
sensit
qualit
pcr
cmv
dna
valu
obtain
inhous
quantit
assay
higher
commerci
assay
differ
quantit
method
includ
report
result
genom
copiesml
copiesml
copi
microgram
total
dna
leukocyt
leukocyt
vari
quantit
method
make
comparison
result
almost
imposs
clearli
defin
cutoff
valu
determin
cmv
diseas
method
low
specif
low
posit
predict
valu
cmv
cutoff
plasma
rang
copiesml
cmv
dna
antivir
suscept
test
cmv
isol
gener
resist
cmv
antivir
major
clinic
problem
patient
aid
current
market
anticmv
drug
name
ganciclovir
gcv
oral
prodrug
valganciclovir
vgcv
foscarnet
fo
cidofovir
cdv
target
viral
dna
polymeras
cmv
infect
remain
major
problem
transplant
resist
antivir
encount
form
transplant
gener
take
week
month
cmv
develop
resist
antivir
patient
aid
studi
show
preval
resist
ganciclovir
month
therapi
similar
time
cours
found
foscarnet
cidofovir
phenotyp
method
plaqu
reduct
assay
gold
standard
antivir
suscept
test
cmv
plaqu
reduct
assay
assay
standard
inoculum
stock
viru
inocul
cultur
incub
presenc
antivir
agent
cultur
observ
presenc
viral
plaqu
agent
isol
defin
concentr
agent
caus
reduct
number
plaqu
produc
plaqu
reduct
assay
laborintens
plaqu
reduct
assay
limit
excess
time
requir
complet
assay
week
lack
standard
method
valid
across
differ
laboratori
addit
repeat
passag
isol
prepar
viral
stock
may
influenc
result
assay
select
cmv
strain
repres
origin
popul
virus
dna
hybrid
assay
whole
genom
dna
extract
transfer
capillari
action
onto
neg
charg
nylon
membran
incub
specif
agent
membran
hybrid
human
cmv
probe
diagnost
hybrid
athen
ohio
rins
wash
count
gamma
counter
mean
hybrid
valu
count
per
minut
cpm
concentr
antivir
agent
calcul
express
percentag
cpm
control
cultur
defin
concentr
antivir
agent
result
reduct
viral
nucleic
acid
hybrid
valu
ie
dna
synthesi
compar
hybrid
valu
control
disadvantag
dna
hybrid
assay
requir
use
radiolabel
probe
dna
hybrid
assay
advantag
plaqu
reduct
assay
elimin
variat
due
subject
error
result
plaqu
count
differ
individu
viral
load
assay
eg
antigenemia
quantit
dna
cmv
viral
load
assay
may
rise
indic
antivir
resist
factor
includ
complianc
declin
immun
function
may
respons
assay
measur
viral
dna
concentr
expos
rang
drug
concentr
grown
day
presenc
absenc
drug
determin
quantit
antigenemia
assay
less
exact
quantit
polymeras
chain
reaction
mani
patient
certain
cmv
diseas
eg
gastrointestin
diseas
retin
alway
associ
measur
viral
load
phenotyp
method
viral
product
measur
use
intern
competitor
dna
ssdna
confirm
known
number
namalwa
cell
b
cell
lymphoma
cell
line
contain
two
integr
copi
ebv
genom
per
cell
four
separ
pcr
reaction
tube
contain
intern
competitor
dna
copiesml
copiesml
copi
ml
copiesml
place
competit
ebvspecif
primer
amplif
patient
dna
pcr
amplicon
examin
electrophoresi
agaros
gel
visual
use
gel
imag
document
system
band
densiti
quantit
measur
use
biorad
quantiti
one
softwar
use
calcul
ebv
copi
although
highli
accur
reproduc
assay
rather
labori
requir
intens
postpcr
handl
sampl
spike
differ
amount
intern
standard
achiev
precis
quantif
realtim
pcr
lightcycl
ebv
quantit
kit
roch
detect
lmp
gene
ebv
viral
genom
ebv
amplifi
specif
primer
pcr
reaction
amplicon
detect
fluoresc
use
specif
pair
hybrid
probe
melt
curv
analysi
perform
pcr
run
differenti
posit
sampl
nonebv
speci
ie
herp
viru
famili
intern
control
synthet
doublestrand
dna
molecul
primer
bind
site
ident
ebv
target
sequenc
compris
uniqu
hybrid
probe
bind
region
differenti
intern
control
targetspecif
amplicon
ad
alreadi
lyse
sampl
purif
step
copurifiedamplifi
ebv
dna
specimen
pcr
reaction
dual
color
detect
kit
allow
quantif
rang
copi
per
reaction
lower
detect
limit
kit
copi
per
reaction
confid
interv
probit
analysi
commerci
assay
reagent
commerci
assay
reagent
includ
nanogen
ebv
qpcr
realtim
pcr
use
sybr
green
dye
maxim
detect
rate
reduc
falseneg
result
two
primer
set
target
highli
conserv
ebv
region
epsteinbarr
nuclear
antigen
bamhi
fragment
h
rightward
open
read
frame
use
detect
measur
absolut
ebv
dna
load
clinic
set
differ
ebvassoci
diseas
two
separ
realtim
quantit
pcr
assay
use
sybr
green
dye
singl
quantif
standard
contain
two
ebv
gene
pcr
product
analyz
amplif
curv
melt
analys
amplif
effici
lower
limit
detect
ebv
region
copiesml
sensit
costeffect
pitfal
quantit
pcr
requir
analysi
absolut
lymphocyt
count
invers
affect
viremia
realtim
pcr
import
note
realtim
pcr
assay
requir
sequenti
analysi
run
data
prior
result
report
prevent
fals
posit
ie
pseudoamplif
amplif
nonebv
speci
fals
neg
ie
shift
melt
curv
ebv
variant
pcr
assay
standard
variat
sampl
handl
laboratori
method
affect
sensit
assay
serial
viral
load
test
use
monitor
diseas
burden
assess
efficaci
immunosuppress
therapi
posttranspl
patient
varicella
chicken
pox
chicken
pox
caus
vzv
one
contagi
childhood
diseas
nearli
everi
unvaccin
child
becom
infect
mild
selflimit
ill
common
schoolag
children
fever
follow
vesicular
erupt
skin
mucou
membran
spread
respiratori
secret
day
incub
period
sever
adult
pneumonia
common
herp
zoster
shingl
recurr
infect
usual
adult
may
activ
trauma
neoplasm
immunosuppress
viru
remain
latent
sensori
ganglia
spinal
cranial
nerv
caus
dermatom
pain
vesicular
erupt
fever
malais
commonli
occur
trunk
may
affect
dermatom
associ
enceph
delay
cerebr
vascul
zoster
sine
herpet
occur
event
recurr
absenc
vesicl
format
post
herpet
neuralgia
pain
last
longer
month
episod
occur
mani
affect
individu
particularli
year
age
neuralgia
resolv
within
one
year
experienc
resolut
within
month
ramsay
hunt
syndrom
combin
cutan
involv
herp
zoster
infect
extern
auditori
canal
ipsilater
facial
auditori
nerv
syndrom
caus
facial
paralysi
hear
deficit
vertigo
specimen
skin
vesicl
fluid
cerebrospin
fluid
nasopharyng
secret
bronchial
wash
blood
amniocentesi
fluid
urin
convent
test
problem
tabl
viral
cultur
convent
especi
also
recogn
necessari
factor
develop
cervic
cancer
genom
hpv
viru
circular
fig
genom
eight
open
read
frame
encod
ten
protein
gene
divid
earli
region
express
skin
infect
basal
cell
yet
differenti
late
region
two
gene
whose
protein
product
exist
cell
cell
differenti
chang
cellular
respons
program
cell
death
apoptosi
bind
tumor
suppressor
protein
bind
inactiv
retinoblastoma
protein
rb
protein
earli
viral
protein
express
upon
infect
caus
destabil
infect
cell
induc
replic
cell
differenti
migrat
upward
induc
express
gene
caus
viral
replic
destabil
cytoskeleton
prevent
cellular
differenti
upper
epitheli
cell
layer
late
viral
protein
major
capsid
protein
minor
capsid
protein
express
bind
viral
dna
autoassembl
give
rise
complet
virion
readi
new
infect
releas
keratinocyt
desquam
common
mode
transmiss
via
contact
ie
sexual
autoinocul
hpv
far
common
sexual
transmit
diseas
estim
sexual
activ
adult
infect
one
genit
hpv
strain
vast
major
infect
adult
experi
transient
infect
unawar
condit
howev
may
abl
infect
other
howev
women
infect
highrisk
hpv
especi
women
year
age
develop
cervic
cancer
immun
system
effect
clear
infect
cours
sever
month
specif
factor
determin
hpv
infect
persist
develop
squamou
intraepitheli
lesion
current
unknown
cigarett
smoke
ultraviolet
radiat
pregnanc
folat
defici
immun
suppress
implic
possibl
cofactor
lowrisk
hpv
type
produc
benign
epitheli
tumor
skin
mucou
membran
infect
certain
type
hpv
high
risk
also
increas
risk
develop
cervic
cancer
type
condit
associ
hpv
verruca
vulgari
common
wart
associ
highli
contagi
spread
site
skin
mucou
membran
via
autoinocul
condyloma
acuminatum
vener
wart
associ
consid
sexual
transmit
diseas
lesion
occur
site
sexual
contact
trauma
ie
mucou
membran
genitalia
perian
region
oral
caviti
larynx
flat
wart
commonli
found
face
forehead
common
children
teen
plantar
wart
found
sole
feet
subungu
periungu
wart
form
fingernail
subungu
around
fingernail
cuticl
periungu
subtyp
common
skin
wart
may
difficult
cure
wart
locat
butcher
wart
caus
occur
peopl
handl
meat
poultri
fish
focal
epitheli
hyperplasia
heck
diseas
caus
possibl
commonli
occur
nativ
american
inuit
popul
childhood
condit
character
multipl
soft
nontend
flat
papul
plaqu
oral
mucou
membran
laryng
papillomatosi
frequent
recur
may
requir
repetit
surgeri
interfer
breath
rare
case
progress
laryng
cancer
hivassoci
papillomatosi
immunocompromis
state
cervic
cancer
histori
hpv
highrisk
type
infect
strongli
associ
develop
cervic
cancer
howev
hpv
infect
progress
cervic
cancer
progress
transform
normal
cervic
cancer
cell
slow
process
cancer
occur
peopl
infect
hpv
long
time
usual
decad
highrisk
hpv
type
togeth
respons
cervic
cancer
case
type
alon
caus
cervic
cancer
analrect
cancer
although
rare
anal
rectal
cancer
becom
preval
us
similar
cervic
cancer
main
caus
anal
cancer
hpv
commonli
acquir
anal
intercours
howev
anal
cancer
also
acquir
genit
area
infect
hpv
particularli
vulva
peni
highrisk
hpv
type
associ
anal
squamou
intraepitheli
lesion
account
approxim
cervic
anal
cancer
head
neck
squamou
cell
cancer
common
type
detect
head
neck
squamou
cell
cancer
hnscc
account
hpvposit
oropharyng
case
hpv
type
account
oropharyng
oral
caviti
laryng
hpvposit
scc
genotyp
associ
better
prognosi
squamou
cell
carcinoma
head
neck
furthermor
hpvposit
tumor
also
sensit
radiat
chemotherapi
coinfect
possibl
frequent
includ
often
report
identifi
hpvposit
hnscc
numer
hpv
type
rare
detect
hnscc
includ
type
use
tissu
section
liquidbas
cytolog
specimen
cervic
smear
slide
detect
highand
lowrisk
hpv
genotyp
probe
cocktail
highrisk
hpv
genotyp
probe
cocktail
lowrisk
hpv
genotyp
nucleic
acid
hybrid
digen
hybrid
captur
ii
digen
corpor
gaithersburg
md
method
util
rna
probe
mix
detect
gene
hpv
assay
identifi
hr
hpv
type
addit
kit
detect
lowrisk
viru
also
avail
manual
semiautom
rapid
captur
autom
util
qiagen
qiasymphoni
extract
system
platform
avail
signal
amplif
base
immunocaptur
dnarna
hybrid
immobil
micropl
react
alkalin
phosphataseconjug
antibodi
specif
rna
dna
hybrid
detect
chemiluminesc
substrat
detect
viral
copi
per
sampl
one
picogram
hpv
dna
per
sampl
signal
amplif
invad
assay
cervista
hpv
assay
holog
madison
wi
invad
assay
isotherm
linear
signal
amplif
use
structurespecif
oligonucleotid
cleavag
appli
dnabas
genotyp
method
use
two
type
isotherm
reaction
primari
reaction
occur
target
dna
sequenc
secondari
reaction
produc
fluoresc
signal
invad
util
intern
control
human
assur
dna
qualiti
quantiti
reaction
two
diagnost
qualit
assay
format
util
invad
chemistri
avail
cervista
hpv
hr
detect
pool
hpv
genotyp
cervista
detect
andor
cervista
hpv
hr
use
isotherm
signal
amplif
detect
h
hpv
type
util
three
probe
pool
base
phylogen
related
probe
pool
includ
pool
assay
determin
specif
hpv
genotyp
present
cervista
test
diagnost
test
genotyp
cervic
specimen
detect
viral
copi
per
specimen
target
amplif
tma
aptima
hpv
assay
genprob
san
diego
ca
aptima
hpv
assay
vitro
nucleic
acid
amplif
test
qualit
detect
viral
messeng
rna
mrna
highrisk
type
hpv
cervic
specimen
detect
hpv
subtyp
distinguish
highrisk
type
assay
use
tigri
dt
system
one
first
diagnost
instrument
truli
autom
nucleic
acid
test
nat
start
finish
sampl
prepar
amplif
detect
report
result
tigri
system
process
approxim
sampl
shift
sampl
approxim
h
aptima
hpv
assay
involv
three
main
step
mainli
target
captur
target
amplif
transcriptionmedi
amplif
tma
detect
amplif
product
amplicon
hybrid
protect
assay
hpa
measur
emit
rel
light
unit
rlu
luminomet
detect
viral
copi
per
sampl
realtim
pcr
coba
hpv
test
roch
diagnost
indianapoli
coba
hpv
test
clinic
diagnost
qualit
assay
detect
hpv
patient
sampl
use
coba
system
autom
specimen
extract
amplif
detect
assay
util
amplif
hpv
dna
realtim
pcr
nucleic
acid
hybrid
detect
highrisk
hpv
genotyp
singl
reaction
tube
target
polymorph
region
hpv
genom
assay
specif
genotyp
concurr
detect
highrisk
genotyp
pool
fashion
coba
hpv
test
base
two
major
process
autom
specimen
prepar
simultan
extract
hpv
cellular
dna
pcr
amplif
target
dna
sequenc
use
hpvand
bglobinspecif
complementari
primer
pair
realtim
detect
cleav
fluorescentlabel
hpvand
bglobinspecif
oligonucleotid
detect
probe
master
mix
reagent
coba
hpv
test
contain
primer
pair
probe
specif
highrisk
hpv
type
bglobin
dna
detect
amplifi
dna
amplicon
perform
thermal
cycl
use
oligonucleotid
probe
label
four
differ
fluoresc
dye
amplifi
signal
highrisk
hpv
type
detect
use
fluoresc
dye
bglobin
signal
detect
dedic
fluoresc
dye
addit
primer
pair
probe
target
human
bglobin
gene
amplicon
provid
process
control
detect
viral
copiesml
genotyp
roch
linear
array
fig
qualit
test
util
amplif
hpv
target
dna
pcr
nucleic
acid
hybrid
base
four
major
step
sampl
prepar
pcr
amplif
target
dna
use
hpvspecif
complementari
primer
hybrid
amplifi
product
oligonucleotid
probe
colorimetr
detect
probebound
amplifi
product
use
pool
biotinyl
primer
defin
sequenc
nucleotid
region
hpv
genom
design
amplifi
hpv
dna
hpv
genotyp
includ
highrisk
genotyp
bglobulin
gene
concurr
isol
ensur
adequaci
cellular
extract
amplif
process
sampl
sensit
specif
overal
sensit
cytolog
detect
hgsil
rang
specif
overal
sensit
hpv
dna
test
detect
hgsil
specif
overal
sensit
coba
hpv
assay
detect
hgsil
specif
overal
sensit
cervista
hpv
assay
detect
hgsil
specif
overal
sensit
aptima
hpv
test
detect
hgsil
specif
howev
sensit
specif
influenc
age
preval
tabl
pitfal
present
avail
assay
provid
qualit
result
correl
magnitud
posit
assay
signal
meaning
quantit
result
effect
potenti
variabl
vagin
discharg
use
tampon
douch
person
lubric
topic
medica
specimen
collect
variabl
may
affect
perform
assay
neg
hpv
result
exclud
possibl
present
futur
cytolog
abnorm
coba
hpv
assay
fig
roch
linear
array
hpv
genotyp
assay
refer
guid
util
interpret
p
posit
control
n
neg
control
globulin
low
globulin
high
pap
smear
result
determin
need
referr
colposcopi
result
test
intend
prevent
women
proceed
colposcopi
tabl
women
year
older
highrisk
hpv
dna
test
use
pap
smear
adjunct
screen
assess
presenc
absenc
highrisk
hpv
type
inform
togeth
physician
assess
cytolog
histori
risk
factor
profession
guidelin
may
use
guid
patient
manag
tabl
recent
new
test
scheme
propos
fig
influenza
b
c
virus
influenza
part
orthomyxovirida
famili
classifi
three
basic
type
influenza
b
c
tabl
influenza
viru
type
envelop
singlestrand
rna
viru
share
specimen
tabl
nasopharyng
aspirateswabwash
tracheal
aspir
bronchoalveolar
lavag
transport
culturedfa
ml
minimum
ml
respiratori
sampl
viral
transport
media
microtest
steril
leakproof
contain
c
serolog
ml
minimum
ml
serum
sst
tube
c
unaccept
specimen
dri
swab
wood
calcium
algin
swab
may
inactiv
viru
cultur
plasma
hemolyz
lipem
icter
turbid
bacteri
contamin
heatinactiv
serum
inadequ
serolog
test
influenza
virus
infect
bird
call
avian
influenza
virus
commonli
known
bird
flu
influenza
virus
subtyp
infect
bird
substanti
genet
differ
subtyp
typic
infect
peopl
bird
within
subtyp
avian
influenza
virus
also
differ
strain
incub
period
avian
influenza
viru
typic
day
long
day
influenza
virus
occur
natur
among
bird
wild
bird
worldwid
carri
virus
intestin
usual
get
sick
howev
avian
influenza
contagi
among
bird
make
domest
bird
includ
chicken
duck
turkey
sick
kill
mani
differ
subtyp
type
influenza
virus
fig
subtyp
differ
chang
certain
protein
surfac
influenza
viru
hemagglutinin
neuraminidas
protein
known
hemagglutinin
subtyp
known
neuraminidas
subtyp
influenza
virus
mani
differ
combin
hemagglutinin
neuraminidas
protein
possibl
combin
repres
differ
subtyp
avian
influenza
virus
distinguish
low
pathogen
high
pathogen
form
basi
genet
featur
viru
sever
ill
caus
poultri
influenza
viru
identifi
low
pathogen
form
three
avian
influenza
virus
theoret
partner
one
nine
neuraminidas
surfac
protein
thu
potenti
nine
differ
form
subtyp
eg
report
sign
symptom
avian
influenza
human
rang
eye
infect
conjunct
influenzalik
ill
symptom
eg
fever
cough
sore
throat
muscl
ach
sever
respiratori
ill
eg
pneumonia
acut
respiratori
distress
sensit
commerci
assay
rang
specif
rang
absolut
sensit
rtpcr
assay
rang
genom
equival
per
reaction
pitfal
present
sar
antibodi
detect
serum
point
cours
diseas
howev
patient
seroconvert
second
week
highlight
import
rtpcr
assay
earli
diagnosi
viru
posit
result
must
confirm
repeat
test
use
aliquot
origin
specimen
andor
anoth
laboratori
report
altern
test
second
gene
region
may
help
furthermor
test
one
sampl
singl
sourc
rule
presenc
sarsassoci
coronaviru
neg
result
rule
sar
presenc
pcr
inhibitor
patient
specimen
poor
rna
qualiti
nucleic
acid
concentr
level
detect
assay
may
occur
first
week
serum
plasma
prefer
rtpcr
week
sampl
type
less
effect
stool
respiratori
sampl
prefer
type
week
stool
prefer
sampl
type
rtpcr
viral
load
upper
respiratori
tract
fece
low
first
day
infect
peak
approxim
day
ill
day
ill
high
viral
load
independ
predictor
poor
clinic
outcom
enterovirus
repres
one
common
human
virus
affect
estim
million
individu
us
potenti
one
billion
worldwid
enteroviru
infect
commonli
occur
temper
zone
summer
earli
fall
enterovirus
divers
group
small
nonenvelop
ssrna
virus
kb
transmit
fecalor
rout
enterovirus
compris
group
human
virus
includ
poliovirus
echovirus
coxsacki
virus
coxsacki
b
virus
variou
enteroviru
subtyp
origin
classif
human
enterovirus
substitut
taxonom
scheme
base
molecular
biolog
properti
virus
revis
classif
recogn
least
subtyp
separ
four
speci
sever
mode
transmiss
exist
virus
includ
fecalor
respiratori
transplacent
perinat
selfinocul
mode
major
fecalor
although
enterovirus
undergo
rapid
replic
gi
tract
rare
caus
signific
gi
diseas
instead
travel
via
bloodstream
target
organ
replic
induc
patholog
alter
infect
subclin
although
may
caus
varieti
acut
chronic
diseas
acut
mild
upper
respiratori
ill
common
cold
febril
rash
hand
foot
mouth
diseas
herpangina
asept
mening
pleurodynia
enceph
acut
flaccid
paralysi
neonat
sepsislik
diseas
chronic
myocard
cardiomyopathi
type
diabet
mellitu
neuromuscular
diseas
highest
incid
enteroviru
infect
infant
young
children
specimen
non
steril
site
nasalthroat
swab
fece
presenc
viru
might
mere
indic
coincident
carriag
steril
site
vesicular
fluid
csf
serum
urin
gather
autopsi
reliabl
sampl
transport
viral
transport
media
either
transport
directli
laboratori
store
c
maximum
convent
test
problem
viral
cultur
shell
vial
cultur
gold
standard
detect
enteroviru
timeconsum
method
insensit
method
reli
presenc
viabl
viru
inabl
fulli
character
enteroviru
strain
associ
late
inadequ
collect
handl
process
sampl
intrins
insensit
cell
line
use
take
day
cpe
appear
viru
present
low
titer
eg
csf
specimen
type
coxsackieviru
grow
cell
cultur
although
shell
vial
cultur
use
monoclon
antibodi
decreas
cultur
time
compar
tube
cultur
less
sensit
convent
cultur
serolog
serotyp
usual
irrelev
individu
manag
absenc
wide
share
antigen
hamper
develop
immunoassay
enteroviru
report
monoclon
antibodi
crossreact
multipl
enteroviru
serotyp
promis
test
requir
determin
clinic
relev
observ
molecular
method
real
time
rtpcr
abi
prism
appli
biosystem
foster
citi
calif
improv
speed
accuraci
use
taqman
assay
platform
target
conserv
sequenc
ntr
vp
capsid
protein
ntr
highli
conserv
region
involv
viral
protein
translat
fig
enteroviru
realtim
taqman
pcr
analysi
serum
plasma
may
good
altern
enteroviru
cultur
fece
particularli
neonat
sepsi
protein
p
polypeptid
nt
nontransl
region
pcr
primer
usual
design
target
nt
region
andiatec
enteroviru
real
time
rtpcr
kit
kit
screen
assay
detect
enterovirus
coxsacki
coxsacki
b
echoviru
capillari
system
lightcycl
roch
target
conserv
sequenc
ntr
cepheid
smartcycl
system
detect
region
ntr
nasba
nasbaelectrochemiluminesc
ecl
nasbabeacon
significantli
differ
sensit
specif
target
conserv
sequenc
ntr
nasbaecl
nuclisen
basic
kit
prove
equal
greater
sensit
detect
enterovirus
nuclisen
basic
kit
amplifi
rna
product
detect
hybrid
use
ecllabel
probe
highli
sensit
methodolog
nasbabeacon
nuclisen
easyq
enteroviru
test
biomerieux
durham
nc
util
realtim
molecular
beacon
probe
nasbabeacon
realtim
rtpcr
use
taqman
shorten
technic
handson
time
time
result
enteroviru
consensu
argen
biosoft
research
use
us
onestep
rtpcr
enteroviru
serotyp
one
singl
reaction
tube
amplifi
region
ncr
genom
detect
perform
biotinyl
enteroviru
gener
probe
sensit
specif
nasbaecl
nasbabeacon
similar
sensit
respect
rtpcr
sensit
cultur
sensit
jc
bk
initi
patient
first
discov
jcv
isol
brain
tissu
patient
progress
multifoc
leukoencephalopathi
pml
bkv
isol
urin
renal
transplant
patient
develop
ureter
stenosi
postop
bkv
jcv
share
homolog
level
nucleotid
sequenc
homolog
simian
viru
belong
polyomavirus
introduc
human
popul
contamin
polio
vaccin
produc
monkey
cell
two
crossreact
serolog
serolog
test
antibodi
abl
distinguish
bkv
jcv
adult
popul
antibodi
bkv
jcv
primari
infect
typic
occur
childhood
initi
infect
polyomavirus
establish
latenc
variou
tissu
primari
site
latenc
uroepitheli
cell
bk
viru
b
lymphocyt
renal
tissu
jcv
addit
site
latenc
virus
includ
uret
brain
spleen
bkv
jcv
associ
human
tumor
recent
evid
may
cofactor
etiolog
specif
human
tumor
type
rais
interest
two
human
polyomavirus
possibl
agent
involv
human
oncogenesi
immunocompet
individu
primari
bkv
infect
usual
caus
mild
respiratori
ill
rare
cystiti
wherea
primari
jcv
infect
typic
asymptomat
bkv
seropreval
peak
age
year
old
reactiv
latent
well
primari
bkv
jcv
infect
may
occur
immunocompromis
individu
ie
organ
transplant
aid
leukemia
bkv
infect
lead
interstiti
nephriti
tubul
hemorrhag
cystiti
kidney
allograft
reject
jcv
respons
progress
multifoc
leukoencephalopathi
pml
fatal
demyelin
diseas
central
nervou
system
seen
aid
patient
specimen
urin
plasma
csf
tissu
biopsi
convent
test
problem
cytolog
immunohistocytochemistri
urin
sampl
use
confirm
bkv
reactiv
diagnosi
urin
sampl
stain
jcbk
monoclon
antibodi
viral
cultur
jc
viru
difficult
cultur
sensit
cell
type
jcv
primari
human
fetal
glial
cell
easi
reagent
acquir
bk
viru
grow
common
cell
line
human
diploid
fibroblast
sever
day
week
requir
cpe
evid
serolog
studi
hemagglutin
inhibit
enzymelink
immunosorb
assay
method
measur
titer
antibodi
jcv
bkv
serolog
test
blood
csf
antijcv
bkv
antibodi
use
diagnosi
pml
immunosuppress
individu
antibodi
jcv
bkv
common
mani
patient
pml
immunosuppress
patient
fail
develop
signific
rise
antivir
antibodi
titer
serum
csf
molecular
method
fig
pcr
quantit
seminest
pcr
measur
serum
bkv
dna
shown
higher
specif
posit
predict
valu
detect
bkv
nephropathi
also
shown
sensit
detect
bkv
nephropathi
serial
quantif
bkv
dna
level
pcr
aid
manag
bkv
nephriti
measur
increas
decreas
activ
level
noninvas
pcr
analysi
jcv
dna
spinal
fluid
noninvas
method
detect
activ
jcv
infect
specif
sensit
jcbk
consensu
complet
kit
argen
biosoft
us
research
use
kit
detect
type
jc
bk
virus
pcr
hybrid
microwel
plate
offer
high
sensit
copi
per
pcr
bkv
copi
per
pcr
jcv
primer
probe
product
design
amplifi
jcv
bkv
use
nucleas
realtim
assay
target
sequenc
correspond
fragment
bp
locat
gene
larg
antigen
realtim
taqman
pcr
lightcycl
probe
homebrew
target
highli
conserv
sequenc
jcv
bkv
genom
gene
sensit
specif
analyt
specif
crossreact
hsv
famili
virus
simian
viru
adenoviru
hiv
absolut
sensit
jcbk
viru
detect
pcr
abl
detect
jcv
csf
pml
patient
specif
diagnosi
influenc
choic
primer
extract
method
approach
pitfal
sequenc
variat
polyomaviru
genom
within
variou
jcbk
subtyp
may
caus
difficulti
primer
probe
design
competit
jc
bk
virus
due
sensit
may
lead
falseneg
pcr
result
detect
viru
pcr
may
indic
activ
infect
therefor
identif
viral
dna
may
warrant
institut
antivir
therapi
andor
decreas
immunosuppress
therapi
determin
viral
dna
presenc
concentr
transplant
patient
use
establish
caus
allograft
reject
viral
load
may
also
use
immunocompromis
patient
bkv
nephropathi
associ
bk
viremia
copiesml
plasma
bk
viremia
copiesml
seen
approxim
kidney
transplant
recipi
though
latenc
typic
associ
absenc
viremia
low
level
copiesml
plasma
seen
asymptomat
individu
